Abstract
The tumor-suppressing effects of SipB160/HPV16 E7 fusion protein, derived from human papillomavirus, and expressed in Salmonella enterica serovar typhimurium, were evaluated in a cervical cancer model. The expressed E7 protein resulted in efficacious cytotoxicity and tumor growth retardation in TC-1 cervical cancer cells. In addition, in mice bearing TC-1 tumors, live cells of Salmonella expressing HPV16 E7 were administered orally and induced immune responses through interferon-gamma and tumor necrosis factor-alpha cytokine secretion and also suppressed tumor growth (45 %) and prolonged survival (70 %) compared with the control group. These results suggested that the SipB160/HPV16 E7 fusion protein may be a candidate cancer therapeutic agent.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Bacterial Proteins / administration & dosage
-
Bacterial Proteins / genetics
-
Bacterial Proteins / metabolism
-
Biological Products / administration & dosage
-
Biological Products / metabolism*
-
Disease Models, Animal
-
Female
-
Membrane Proteins / administration & dosage
-
Membrane Proteins / genetics
-
Membrane Proteins / metabolism
-
Metabolic Engineering*
-
Mice
-
Papillomavirus E7 Proteins / administration & dosage
-
Papillomavirus E7 Proteins / genetics
-
Papillomavirus E7 Proteins / metabolism*
-
Recombinant Fusion Proteins / administration & dosage
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / metabolism
-
Salmonella typhimurium / genetics*
-
Salmonella typhimurium / metabolism*
-
Survival Analysis
-
Uterine Cervical Neoplasms / therapy*
Substances
-
Bacterial Proteins
-
Biological Products
-
Membrane Proteins
-
Papillomavirus E7 Proteins
-
Recombinant Fusion Proteins
-
invasion protein B, Salmonella typhimurium